Omnicell Inc OMCL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
EnlivenHealth Highlights VaxReach Ahead of ThoughtSpot 2026 — Designed to Help Pharmacies Strengthen Communities Through Vaccination
-
Omnicell Announces Second Quarter 2026 Financial Results
-
Omnicell to Release Second Quarter 2026 Financial Results on July 30, 2026
-
Nnamdi Njoku Appointed President of Omnicell
-
Omnicell Selects Dan Mandoli to Lead Specialty Pharmacy Services Business
-
Omnicell to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
Trading Information
- Previous Close Price
- $36.86
- Day Range
- $35.95–37.27
- 52-Week Range
- $29.06–55.00
- Bid/Ask
- $35.35 / $37.73
- Shares Outstanding
- 45.61M
- Market Cap
- $1.69B
- Volume/Avg
- 10 / 718,816
Key Statistics
- Price/Earnings (Normalized)
- 15.41
- Price/Sales
- 1.37
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 3.66%
Company Profile
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
- Sector
- Healthcare
- Industry
- Health Information Services
- Stock Style Box
- Small Core
- Total Number of Employees
- 3,525
- Website
- https://www.omnicell.com
Competitors
Valuation
|
Metric
|
OMCL
|
CAH
|
MCK
|
|---|---|---|---|
Price/Earnings (Normalized) | 15.41 | 20.80 | 22.45 |
Price/Book Value | 1.31 | — | — |
Price/Sales | 1.37 | 0.22 | 0.26 |
Price/Cash Flow | 9.34 | 15.80 | 17.50 |
Price/Earnings
OMCL
CAH
MCK
Financial Strength
|
Metric
|
OMCL
|
CAH
|
MCK
|
|---|---|---|---|
Quick Ratio | 1.19 | 0.43 | 0.50 |
Current Ratio | 1.64 | 0.88 | 0.89 |
Interest Coverage | — | 7.25 | 23.83 |
Quick Ratio
OMCL
CAH
MCK
Profitability
|
Metric
|
OMCL
|
CAH
|
MCK
|
|---|---|---|---|
Return on Assets (Normalized) | 5.48% | 4.62% | 5.95% |
Return on Equity (Normalized) | 8.80% | — | — |
Return on Invested Capital (Normalized) | 7.25% | 46.33% | 56.43% |
Return on Assets
OMCL
CAH
MCK
Health Information Services Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Veeva Systems Inc Class A
VEEV
| LOCK|kxv@nJl | LOCK|XV | $39B | |||
| Pro Medicus Ltd
PMCUF
| — | LOCK|&$l$> | $13B | |||
| Pro Medicus Ltd ADR
PMDIY
| — | LOCK|B&%# | $13B | |||
| BrightSpring Health Services Inc
BTSG
| — | LOCK|q!gt | $12B | |||
| Tempus AI Inc Class A common stock
TEM
| — | LOCK|<C% | $10B | |||
| HealthEquity Inc
HQY
| — | LOCK|?lrr | $9B | |||
| 10x Genomics Inc Ordinary Shares - Class A
TXG
| — | LOCK|%xwMf | $8B | |||
| Hinge Health Inc Ordinary Shares - Class A
HNGE
| — | LOCK|>w# | $7B | |||
| M3 Inc ADR
MTHRY
| — | LOCK|Ql$> | $7B | |||
| Waystar Holding Corp
WAY
| — | LOCK|$@ | $5B |
United States